GSA Capital Partners LLP Invests $688,000 in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

GSA Capital Partners LLP bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 20,722 shares of the company's stock, valued at approximately $688,000.

A number of other institutional investors have also recently added to or reduced their stakes in HRMY. FMR LLC lifted its holdings in Harmony Biosciences by 1.9% during the fourth quarter. FMR LLC now owns 5,329,902 shares of the company's stock valued at $183,402,000 after purchasing an additional 101,182 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after purchasing an additional 1,262,362 shares during the last quarter. Deep Track Capital LP acquired a new position in shares of Harmony Biosciences during the 4th quarter worth about $49,894,000. Dimensional Fund Advisors LP lifted its stake in Harmony Biosciences by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,213,029 shares of the company's stock valued at $41,739,000 after buying an additional 160,490 shares in the last quarter. Finally, LSV Asset Management boosted its holdings in Harmony Biosciences by 23.8% in the 4th quarter. LSV Asset Management now owns 956,217 shares of the company's stock worth $32,903,000 after buying an additional 184,026 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HRMY. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 8th. Cantor Fitzgerald raised Harmony Biosciences to a "strong-buy" rating in a research note on Tuesday, May 13th. UBS Group lowered their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $55.00 target price (up previously from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a research note on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Harmony Biosciences currently has a consensus rating of "Buy" and an average target price of $51.00.

Harmony Biosciences Trading Down 2.2%

Shares of HRMY opened at $34.40 on Friday. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The firm has a market capitalization of $1.98 billion, a P/E ratio of 13.13, a P/E/G ratio of 0.47 and a beta of 0.84. The firm has a 50-day moving average price of $34.09 and a 200 day moving average price of $33.96. The company has a current ratio of 3.67, a quick ratio of 3.63 and a debt-to-equity ratio of 0.22.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. The company had revenue of $184.73 million for the quarter, compared to analyst estimates of $184.26 million. Harmony Biosciences had a net margin of 20.53% and a return on equity of 24.32%. Harmony Biosciences's revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 EPS. Sell-side analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.